June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Safety and efficacy of CRISPR-based genome ablation of VEGFA as treatment for choroidal neovascularization in nonhuman primate eyes.
Author Affiliations & Notes
  • Tzu-Ni Sin
    Ophthalmology, University of California Davis, Davis, California, United States
  • Carol Villafuerte-Trisolini
    Ophthalmology, University of California Davis, Davis, California, United States
  • Sook Hyun Chung
    Ophthalmology, University of California Davis, Davis, California, United States
  • Lien Tu
    Ophthalmology, University of California Davis, Davis, California, United States
  • Sara M Thomasy
    Surgical & Radiological Sciences, University of California Davis, Davis, California, United States
  • Ala Moshiri
    Ophthalmology, University of California Davis, Davis, California, United States
  • Glenn Yiu
    Ophthalmology, University of California Davis, Davis, California, United States
  • Footnotes
    Commercial Relationships   Tzu-Ni Sin None; Carol Villafuerte-Trisolini None; Sook Hyun Chung None; Lien Tu None; Sara Thomasy None; Ala Moshiri None; Glenn Yiu Abbvie, Adverum, Alimera, Bausch & Lomb, Clearside, Endogena, Genentech, Gyroscope, Intergalactic, Iridex, Janssen, Myro, NGM Bio, Novartis, Regeneron, Thea, Topcon, Zeiss, Code C (Consultant/Contractor)
  • Footnotes
    Support  BrightFocus Foundation Macular Degeneration grant
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3257. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tzu-Ni Sin, Carol Villafuerte-Trisolini, Sook Hyun Chung, Lien Tu, Sara M Thomasy, Ala Moshiri, Glenn Yiu; Safety and efficacy of CRISPR-based genome ablation of VEGFA as treatment for choroidal neovascularization in nonhuman primate eyes.. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3257.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : CRISPR-based genome editing enables permanent suppression of pro-angiogenic factors like vascular endothelial growth factor (VEGF) and overcomes the burden of frequent intravitreal injections in patients with neovascular age-related macular degeneration (nAMD). We previously designed adeno-associated viral (AAV) vectors with S. pyogenes Cas 9 (SpCas9) and single guide RNAs (gRNAs) to target conserved regions in exon 1 of VEGFA across mice, rhesus macaques, and humans, with successful suppression of laser-induced choroidal neovascularization (CNV) in mouse eyes. Here we report the preclinical safety and efficacy of adapting this AAV-CRISPR system to target VEGFA in nonhuman primate eyes.

Methods : We subretinally injected dual AAV8 vectors (6E11 - 6E12 vg/eye) to express SpCas9 and gRNAs targeting VEGFA or empty control into 6 adult rhesus macaque eyes followed by induction of laser CNV 4 weeks later. Clinical examination and multimodal imaging including fundus photography (FP), fundus autofluorescence (FAF), fluorescein angiography (FA), and optical coherence tomography (OCT) were performed at 2-week intervals. Aqueous, serum, and PBMCs were collected monthly to measure neutralizing antibodies (NAbs) and T-cells against AAV8 and transgenes. Retinal tissues were collected at 3 months for deep sequencing and ELISA to analyze genome editing rate and VEGFA protein levels.

Results : Submacular injections of the dual AAV8 vectors did not trigger clinical signs of anterior chamber or vitreous inflammation at all doses, but generated concentric macular rings on FAF imaging, which corresponded to outer retinal atrophy on OCT and was more prominent at 6E12 vg/eye, intraretinal hyperreflective foci, and subfoveal accumulation of hyperreflective material, starting as early as 2 weeks after injection and persisted until the terminal point at 12 weeks, with no clear difference between the two groups. Masked grading of CNV severity from FA images showed a non-significant trend toward lower CNV severity in eyes that received SpCas9 with gRNAs targeting VEGFA.

Conclusions : AAV-mediated CRISPR-based gene ablation of VEGFA demonstrated no significant suppression of laser-induced CNV in rhesus macaque eyes, with evidence of retinal thinning and photoreceptor disruption that may be associated with retinal inflammation.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×